Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02090530 |
Recruitment Status :
Recruiting
First Posted : March 18, 2014
Last Update Posted : September 18, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Cancer | Other: Biospecimen collection |
Study Type : | Observational |
Estimated Enrollment : | 1000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Precision Cancer Medicine for Advanced Cancer Through High-throughput Sequencing |
Actual Study Start Date : | November 4, 2013 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | December 31, 2023 |
Group/Cohort | Intervention/treatment |
---|---|
Advanced Cancer Patients
Individuals with advanced or refractory cancer must be identified by study personnel or their treating physician, deemed eligible for this study, and voluntarily agree to be enrolled in this protocol through an informed consent. Biospecimen collection includes a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
|
Other: Biospecimen collection
Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear. |
- Number of participants receiving new therapy based on study findings [ Time Frame: Up to 24 Months ]Impact on clinical care
- Average number of days to return results [ Time Frame: Up to 24 months ]Determine average number of days for return of results
Biospecimen Retention: Samples With DNA
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- A histologically or cytologically confirmed diagnosis of cancer
- Patients with any malignancy.
-
Patients must have tumor suitable for research tumor biopsy (as assessed by trained specialists in interventional radiology) and Patients are medically fit to undergo a tissue biopsy or surgical procedure to get tumor tissue OR If Patients do not have a tumor suitable for biopsy but have another tissue available for molecular evaluation.
OR Patients are undergoing standard of care surgeries or procedures where fresh specimens will be first used for routine pathologic assessment and only then will leftover tissue be used for research purposes.
- Procedure-specific signed informed consent prior to initiation of any study-related procedures.
- Women and minorities are included in this protocol.
- Patients with multiple malignancies remain eligible.
- Patients with an inherited cancer syndrome or a medical history suggestive of an inherited cancer syndrome remain eligible.
Exclusion Criteria:
- It is the enrolling study physicians discretion to decide if a patient is not fit enough to undergo tissue biopsy.
- Patients who are incarcerated are not eligible to participate.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02090530
Contact: Ohio State University Comprehensive Cancer Center | 1-800-293-5066 | OSUCCCClinicaltrials@osumc.edu | |
Contact: Sameek Roychowdhury, MD, PhD | 614-685-5842 | Sameek.Roychowdhury@osumc.edu |
United States, Ohio | |
Ohio State University Wexner Medical Center | Recruiting |
Columbus, Ohio, United States, 43210 | |
Contact: Sameek Roychowdhury, MD, PhD 614-685-5842 Sameek.Roychowdhury@osumc.edu | |
Principal Investigator: Sameek Roychowdhury, MD, PhD |
Principal Investigator: | Sameek Roychowdhury, MD, PhD | Ohio State University Wexner Medical Center |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Sameek Roychowdhury, Principal Investigator, Ohio State University Comprehensive Cancer Center |
ClinicalTrials.gov Identifier: | NCT02090530 |
Other Study ID Numbers: |
OSU-13053 |
First Posted: | March 18, 2014 Key Record Dates |
Last Update Posted: | September 18, 2023 |
Last Verified: | September 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Cancer Genomics Tumor Sequencing |